BR9609152A - Processo para tratamento de infecção por hiv em um individuo inibição da replicação do hiv e composição farmaceutica aceitavel util para o tratamento de infecção por hiv - Google Patents
Processo para tratamento de infecção por hiv em um individuo inibição da replicação do hiv e composição farmaceutica aceitavel util para o tratamento de infecção por hivInfo
- Publication number
- BR9609152A BR9609152A BR9609152A BR9609152A BR9609152A BR 9609152 A BR9609152 A BR 9609152A BR 9609152 A BR9609152 A BR 9609152A BR 9609152 A BR9609152 A BR 9609152A BR 9609152 A BR9609152 A BR 9609152A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- hiv infection
- hiv
- pharmaceutical composition
- composition useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48195795A | 1995-06-07 | 1995-06-07 | |
PCT/US1996/009499 WO1996040191A1 (en) | 1995-06-07 | 1996-06-06 | The treatment of hiv and other viral infections using combinatory therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9609152A true BR9609152A (pt) | 1999-05-04 |
Family
ID=23914065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9609152A BR9609152A (pt) | 1995-06-07 | 1996-06-06 | Processo para tratamento de infecção por hiv em um individuo inibição da replicação do hiv e composição farmaceutica aceitavel util para o tratamento de infecção por hiv |
Country Status (10)
Country | Link |
---|---|
US (2) | US6475491B1 (pt) |
EP (1) | EP0831873A4 (pt) |
JP (1) | JPH11507632A (pt) |
KR (1) | KR100571215B1 (pt) |
CN (1) | CN1192688A (pt) |
AU (1) | AU723537B2 (pt) |
BR (1) | BR9609152A (pt) |
CA (1) | CA2224008C (pt) |
NZ (1) | NZ311319A (pt) |
WO (1) | WO1996040191A1 (pt) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6479055B1 (en) * | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
US6271198B1 (en) | 1996-11-06 | 2001-08-07 | Genentech, Inc. | Constrained helical peptides and methods of making same |
US6150088A (en) | 1997-04-17 | 2000-11-21 | Whitehead Institute For Biomedical Research | Core structure of gp41 from the HIV envelope glycoprotein |
US6818740B1 (en) | 1997-04-17 | 2004-11-16 | Whitehead Institute For Biomedical Research | Inhibitors of HIV membrane fusion |
US6841657B2 (en) | 1997-04-17 | 2005-01-11 | Whitehead Institute For Biomedical Research | Inhibitors of HIV membrane fusion |
US6747126B1 (en) | 1998-07-30 | 2004-06-08 | Whitehead Institute For Biomedical Research | Peptide inhibitors of HIV entry |
US7960504B2 (en) | 1998-07-30 | 2011-06-14 | Whitehead Institute For Biomedical Research | Inhibitors of HIV membrane fusion |
AU4988900A (en) | 1999-05-05 | 2000-11-17 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | T20/dp178 and t21/dp107 are activators of human phagocyte formyl peptide receptors |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
WO2001044286A2 (en) | 1999-12-16 | 2001-06-21 | Whitehead Institute For Biomedical Research | Five-helix protein |
AU3334001A (en) | 2000-02-10 | 2001-08-20 | Panacos Pharmaceuticals Inc | Assay for detection of viral fusion inhibitors |
WO2001070262A2 (en) * | 2000-03-17 | 2001-09-27 | Panacos Pharmaceuticals, Inc. | A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of hiv envelope proteins |
US20050065319A1 (en) * | 2000-12-19 | 2005-03-24 | Baroudy Bahige M. | Combination method for treating viral infections |
AU2002314111A1 (en) | 2001-06-15 | 2003-01-02 | F. Hoffmann-La Roche Ag | Method for the recombinant production of peptidic antiviral fusion inhibitors, and acetylation of gb41 fragments |
US7094413B2 (en) * | 2002-01-24 | 2006-08-22 | Sangstat Medical Corporation | Combined therapy for treatment of HIV infection |
CA2500248C (en) | 2002-09-24 | 2013-03-19 | Frontier Biotechnologies Co., Ltd. | Peptide derivative fusion inhibitors of hiv infection |
US7556813B2 (en) * | 2002-09-27 | 2009-07-07 | Trimeris, Inc. | Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides |
EP1543166A4 (en) * | 2002-09-27 | 2009-10-28 | Genentech Inc | SYNERGETIC COMPOSITIONS FOR PREVENTING AND TREATING THE ACQUIRED IMMUNE WEAKNESS SYNDROME |
CN105596356A (zh) | 2003-01-14 | 2016-05-25 | 吉里德科学公司 | 用于联合抗病毒治疗的组合物和方法 |
US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
WO2004108885A2 (en) * | 2003-05-06 | 2004-12-16 | Syntonix Pharmaceuticals, Inc. | Fc chimeric proteins with anti-hiv drugs |
WO2004100882A2 (en) * | 2003-05-06 | 2004-11-25 | Syntonix Pharmaceuticals, Inc. | Inhibition of drug binding to serum albumin |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
SI1624891T2 (sl) * | 2003-05-06 | 2013-09-30 | Biogen Idec Hemophilia Inc. | Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije |
WO2005060350A2 (en) * | 2003-12-22 | 2005-07-07 | Yeda Research & Development Co. Ltd. | Diastereomeric peptides useful as inhibitors of membrane protein assembly |
RU2006128593A (ru) * | 2004-01-07 | 2008-02-20 | Тримерис, Инк. (Us) | Синтетические пептиды, производные области hr2 белка gp41 вич, и их применение в терапии для ингибирования проникновения вируса иммунодефицита человека |
EP2354153A3 (en) | 2004-06-01 | 2012-05-30 | Merck Sharp & Dohme Corp. | Stable peptide mimetic of HIV gp41 fusion intermediate |
US20060154895A1 (en) * | 2004-12-09 | 2006-07-13 | Maxwell Gordon | Method of treating acquired immunedeficiency syndrome |
GB0501352D0 (en) * | 2005-01-21 | 2005-03-02 | Slingsby Jason H | Use of glycosylation modulators in combination with membrane fusion inhibitors for treatment of infections caused by viruses bearing glycosylated envelope |
WO2006105993A2 (en) * | 2005-04-05 | 2006-10-12 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Method for shielding functional sites or epitopes on proteins |
CA2651793C (en) * | 2006-02-02 | 2015-07-07 | Trimeris, Inc. | Hiv fusion inhibitor peptides with improved biological properties |
EP1886696A1 (en) * | 2006-08-03 | 2008-02-13 | Endotis Pharma | Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins |
TW200817438A (en) | 2006-08-17 | 2008-04-16 | Hoffmann La Roche | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
KR101105610B1 (ko) | 2006-08-17 | 2012-01-18 | 에프. 호프만-라 로슈 아게 | Ccr5 에 대한 항체 및 항푸소제닉 펩타이드의 컨쥬게이트 |
KR20090098880A (ko) | 2006-12-12 | 2009-09-17 | 바이오렉시스 파마슈티칼 코포레이션 | 트랜스페린 융합 단백질 라이브러리 |
US20090143288A1 (en) * | 2007-03-13 | 2009-06-04 | Roche Palo Alto Llc | Peptide-complement conjugates |
KR20100016142A (ko) * | 2007-04-03 | 2010-02-12 | 트라이머리스, 인코퍼레이티드 | 항바이러스 펩티드 치료제 전달용 신규 제제 |
CL2008002092A1 (es) | 2007-07-20 | 2009-05-29 | Hoffmann La Roche | Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas. |
BRPI0817697A2 (pt) * | 2007-09-25 | 2015-04-07 | Trimeris Inc | Método de síntese de um peptídeo, conjunto de fragmentos de peptídeo, e, peptídeo |
WO2011133948A2 (en) | 2010-04-22 | 2011-10-27 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
RU2013113723A (ru) | 2010-09-14 | 2014-10-20 | Ф.Хоффманн-Ля Рош Аг | Гибридный полипептид с серпиновым "пальцем" |
TWI577377B (zh) | 2010-09-16 | 2017-04-11 | Viiv醫療保健公司 | 醫藥組合物 |
WO2013127300A1 (zh) * | 2012-02-28 | 2013-09-06 | 中国人民解放军军事医学科学院毒物药物研究所 | 用于抑制hiv的多肽、其药物组合物及其用途 |
TWI828269B (zh) | 2013-03-15 | 2024-01-01 | 美商百歐維拉提夫治療公司 | 因子ix多肽調配物 |
US9789164B2 (en) | 2013-03-15 | 2017-10-17 | Longevity Biotech, Inc. | Peptides comprising non-natural amino acids and methods of making and using the same |
US20190328900A1 (en) | 2016-07-01 | 2019-10-31 | Glaxosmithkline Intellectual Property Development Limited | Antibody-drug conjugates and therapeutic methods using the same |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5141867A (en) * | 1987-02-02 | 1992-08-25 | E. I. Du Pont De Nemours And Company | Nucleotide sequence encoding a human immunodeficiency virus antigen |
US4950652A (en) | 1987-03-23 | 1990-08-21 | Hem Research, Inc. | dsRNAs for combination therapy in the treatment of viral diseases |
US5077280A (en) | 1988-04-12 | 1991-12-31 | Brown University Research Foundation | Treatment of viral infections |
GB8815241D0 (en) | 1988-06-27 | 1988-08-03 | Wellcome Found | Antiviral combinations & compounds therefor |
AU641375B2 (en) | 1988-12-20 | 1993-09-23 | Clarity Technologies Incorporated | Synthetic HIV-like peptides, their compositions and uses |
US6248574B1 (en) | 1989-12-13 | 2001-06-19 | Avigdor Shaffermann | Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides |
IL102092A (en) | 1991-06-11 | 1996-11-14 | Microgenesys Inc | Use of recombinant VIH protein wrapped in VIH abduction drug and a pharmaceutical preparation containing the accumulated protein |
AU688733B2 (en) * | 1992-07-20 | 1998-03-19 | Duke University | Compounds which inhibit HIV replication |
US6017536A (en) * | 1993-06-07 | 2000-01-25 | Trimeris, Inc. | Simian immunodeficiency virus peptides with antifusogenic and antiviral activities |
US6479055B1 (en) * | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
US5464933A (en) * | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
-
1996
- 1996-06-06 NZ NZ311319A patent/NZ311319A/xx not_active IP Right Cessation
- 1996-06-06 BR BR9609152A patent/BR9609152A/pt not_active Application Discontinuation
- 1996-06-06 AU AU62619/96A patent/AU723537B2/en not_active Expired
- 1996-06-06 CA CA002224008A patent/CA2224008C/en not_active Expired - Lifetime
- 1996-06-06 US US08/973,952 patent/US6475491B1/en not_active Expired - Lifetime
- 1996-06-06 CN CN96196051A patent/CN1192688A/zh active Pending
- 1996-06-06 WO PCT/US1996/009499 patent/WO1996040191A1/en active IP Right Grant
- 1996-06-06 JP JP9501806A patent/JPH11507632A/ja active Pending
- 1996-06-06 KR KR1019970709127A patent/KR100571215B1/ko not_active IP Right Cessation
- 1996-06-06 EP EP96921379A patent/EP0831873A4/en not_active Ceased
-
2002
- 2002-09-20 US US10/252,136 patent/US6861059B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU6261996A (en) | 1996-12-30 |
KR19990022685A (ko) | 1999-03-25 |
MX9709682A (es) | 1998-06-30 |
JPH11507632A (ja) | 1999-07-06 |
EP0831873A4 (en) | 2002-07-17 |
CA2224008A1 (en) | 1996-12-19 |
EP0831873A1 (en) | 1998-04-01 |
NZ311319A (en) | 2000-01-28 |
CA2224008C (en) | 2009-08-18 |
US6861059B2 (en) | 2005-03-01 |
US6475491B1 (en) | 2002-11-05 |
CN1192688A (zh) | 1998-09-09 |
KR100571215B1 (ko) | 2006-10-24 |
US20030103998A1 (en) | 2003-06-05 |
AU723537B2 (en) | 2000-08-31 |
WO1996040191A1 (en) | 1996-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9609152A (pt) | Processo para tratamento de infecção por hiv em um individuo inibição da replicação do hiv e composição farmaceutica aceitavel util para o tratamento de infecção por hiv | |
BR9610375A (pt) | Extrato de células composição cosmética ou farmacêutica utilização de pelo menos um extrato de células e processo de tratamento cosmético | |
BR8804823A (pt) | Composicao farmaceutica,processo para tratamento de hiv e prevencao de infeccao por hiv em um ser humano e processo para producao de composicao | |
BR9407869A (pt) | Combinaçao composiçao farmacêutica e processo para o tratamento de osteoporose | |
BR9608638A (pt) | Processo e composição farmacêutica para o tratamento seletivo do crescimento e diferenciação de células e composto | |
BR9602542A (pt) | Composto método para o tratamento de uma doença dependente da fosforilase de glicogénio composição farmacéutica e processo para a preparação de um composto | |
BR9606769A (pt) | Tablete e processos para tratamento de uma infecção de vírus do herpes em um humano e para preparação do tablete | |
BR9612204A (pt) | Composto uso do composto composição farmacêutica e processo para preparação do composto e para o tratamento de dor | |
BR9608405A (pt) | Composto composi-Æo farmaceutica e processo para tratar um paciente que sofre de um distÚrbio fisiolÄgico | |
BR9605111A (pt) | Formulação de dosagem farmacêutica oral processo para a manufatura de uma formulação de dosagem fixa método para o tratamento de distúrbios com infecções por helicobacter pylori em mamiferos e no ser humano e uso de uma formulação de dosagem | |
PT861666E (pt) | Composicao farmaceutica para utilizacao no tratamento da diabetes | |
BR9608500A (pt) | Utilização de pelo menos um extrato de pelo menos uma bactéria filamentosa não fotossintética composição cosmética ou farmacêutica e processo de tratamento cosméstico | |
BR9612135A (pt) | Taxóides processo para sua preparação e composiç o farmacêutica | |
PT98944A (pt) | Processo de preparacao de anticorpos alterados e de composicoes farmaceuticas para a prevencao e tratamento de infeccoes | |
BR9609532A (pt) | Composição antimicrobiana para o tratamento de cabelo processo para o tratamento de caspa e uso da composição | |
BR9404114A (pt) | Composição farmacêutica e seu processo de preparação | |
PT100199A (pt) | Combinacao antiviral de nucleosidos e processo para a sua preparacao | |
BR9604089A (pt) | Composição cosmética utilização de um copolímero acrílico e processo de tratamento cosmético de matérias ceratínicas | |
BR9100046A (pt) | Derivados de azaoxindole,composicao farmaceutica e processo para o tratamento de mamiferos | |
BR9607599A (pt) | Ifn-con qumicamente modificado composição farmacêutica preparação processo de tratamento de um paciente possuindo uma condição tratável com ifn-con e processo de liberação de um interferon | |
EE9800234A (et) | Ravimeetod ja farmatseutiline kompositsioon | |
BR9611302A (pt) | Utilização de pelo menos um agonista beta-adrenérgico processo de tratamento cosmético e composição cosmética ou farmacêutica | |
NO960775D0 (no) | Anvendelse av kinoksaliner i kombinasjon med proteaseinhibitorer som legemiddel for behandling av AIDS og/eller HIV-infeksjoner | |
EE04371B1 (et) | Fenüülamidiini derivaadid, meetodid nende valmistamiseks ja nende kasutamine arstimitena | |
BR9602337A (pt) | Composto processo para sua preparação usos do mesmo processo para tratamento de arritmias e medicamento |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: ASSIM SENDO, DE ACORDO COM O ART. 37, INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA (ART. 8 O COMBINADO COM ART. 13 DA LPI) |
|
B12B | Appeal: appeal against refusal |